Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin in RSV-induced Respiratory Failure in Children
NCT02707523Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Jan 2016
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of azithromycin in respiratory syncytial virus infection (RSV) (3 arms), sponsored by University of Alabama at Birmingham. Primary endpoints: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 at Day 3, Nasal Total Matrix Metalloproteinase (MMP)-9 Level at Day 3 and 2 more. Started Jan 2016; status: completed.
02
Drugs
azithromycin
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02707523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02707523.